Skip to main content

Table 1 Simvastatin treatment reduced IL-12p40 levels in plasma

From: Simvastatin attenuates ventilator-induced lung injury in mice

  NV NV + Simva 6 h Vent. 6 h Vent. + Simva
  mean (pg/μl) SD mean (pg/μl) SD mean (pg/μl) SD mean (pg/μl) SD
IL-1β 445.30 100.70 505.30 52.19 763.2 *** 95.38 738.8 ### 100.40
IL-6 57.58 62.99 133.40 90.38 915.3 *** 459.00 993.9 ### 364.60
IL-12p40 462.10 99.32 593.10 128.60 2,352 *** 783.40 1,785 ###, a 372.50
MIP-1α 307.20 149.10 386.50 78.94 918.6 *** 318.60 900.8 ### 128.20
MIP-2 15.28 35.02 10.03 9.42 95.32 ** 49.21 67.25 # 23.73
MCP-1 99.84 17.33 153.50 29.41 758.9 * 404.90 559.70 133.30
  1. Cytokine levels were assessed in blood plasma after 6 h mechanical ventilation (MV) of simvastatin (6 h Vent + Simva) or sham treated mice (6 h Vent.) and in plasma of non-ventilated simvastatin (NV + Simva) or sham (NV) treated mice. MV induced a systemic inflammatory response indicated by elevated cytokine levels in blood. Simvastatin treatment reduced IL-12p40 levels in plasma significantly. The levels of IL-1β, MIP-1α, IL-6, MIP-2 and MCP-1 in VILI did not show statistically significant alterations due to simvastatin treatment. (n = 8 each group; * P < 0.05, ** P < 0.01, *** P < 0.001 vs. NV; # P < 0.05, ### P < 0.001 vs. NV + Simva; a P < 0.05 vs. 6 h Vent.).